Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

Overview of attention for article published in PharmacoEconomics, February 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Readers on

mendeley: 19 Mendeley

Summary X Facebook

So far, Altmetric has seen 1 X post from an account with 721 followers.

#HealthEconJA Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’ https://t.co/RTXteGdVFc

09 Feb 2018

Reply Repost Favourite